Amylyx Pharmaceuticals Reports Q1 2026 Financial Results and Pipeline Updates

Amylyx Pharmaceuticals (NASDAQ:AMLX) reported first-quarter results for fiscal year 2026 with a net loss of $41.3 million, driven by increased R&D expenses related to avexitide development. The company also announced an expanded access program allowing treatment access to up to 250 patients with post-bariatric hypoglycemia.

By Laiba Immad Wed, May 20, 2026 at 11:42 PM GMT+3 2 min read · Yahoo Finance · May 20, 2026, 20:42 UTC

Tickers: $AMLX

Topics: clinical trials pharmaceuticals pipeline progress R&D expenses

Read the full article at Yahoo Finance

More World news

Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Pelagos Insurance Capital Reports Mixed Q3 2026 Results with Revenue Beat and EPS Miss Seeking Alpha · November 12, 2026, 18:01 UTC
Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC